Financial Performance - The company's operating revenue for Q1 2023 was ¥44,485,769.60, representing a 19.35% increase compared to ¥37,272,422.06 in the same period last year[6]. - Net profit attributable to shareholders for Q1 2023 was ¥7,816,548.85, up 9.19% from ¥7,165,807.56 in Q1 2022[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,454,127.50, a significant increase of 49.78% from ¥4,309,093.61 in the previous year[6]. - Basic and diluted earnings per share for Q1 2023 were both ¥0.12, reflecting a 9.09% increase from ¥0.11 in the same quarter last year[6]. - The total operating revenue for the first quarter was CNY 44,485,769.60, an increase of 19.5% compared to CNY 37,272,422.06 in the previous period[28]. - The net profit for the first quarter reached CNY 7,816,548.85, representing a 9.3% increase from CNY 7,149,462.11 in the same period last year[29]. Cash Flow and Liquidity - The net cash flow from operating activities reached ¥19,434,599.35, a remarkable increase of 925.83% compared to a negative cash flow of ¥2,353,328.55 in Q1 2022[6]. - Operating cash flow net amount reached ¥19,434,599.35, a significant improvement from a negative ¥2,353,328.55 in the previous period, indicating a strong recovery in operational performance[33]. - Total cash inflow from operating activities was ¥66,508,610.90, compared to ¥45,011,097.35 in the prior period, reflecting a year-over-year increase of approximately 47.9%[33]. - Cash outflow from operating activities totaled ¥47,074,011.55, slightly decreased from ¥47,364,425.90, showing effective cost management[33]. - The cash and cash equivalents at the end of the period stood at ¥12,837,726.43, down from ¥8,156,838.16, indicating a decrease in liquidity[35]. - The total cash flow from operating, investing, and financing activities resulted in a net decrease of ¥31,925,042.71, compared to a decrease of ¥2,000,667.70 in the prior period, indicating overall cash management challenges[35]. Assets and Liabilities - Total assets at the end of Q1 2023 were ¥728,447,431.74, a decrease of 2.21% from ¥744,919,499.58 at the end of the previous year[6]. - The total liabilities decreased to CNY 118,048,593.35 from CNY 142,337,210.04 in the prior period[27]. - The company reported an increase in other receivables from ¥1,326,619.54 to ¥3,362,187.29 during the reporting period[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,460[16]. - The top two shareholders, Yuan Yuyu and Xu Tao, each hold 16.53% of the shares, totaling 10,922,547 shares[16]. - The top ten unrestricted shareholders hold a total of 11,362,136 shares, representing significant ownership concentration[16]. - The company has a pledge of 3,060,000 shares by shareholder Yuan Yuyu[16]. Government Subsidies and Non-Recurring Gains - The company received government subsidies amounting to ¥695,663.75 during the quarter, contributing to the increase in net profit[12]. - The company reported a total of ¥1,362,421.35 in non-recurring gains for the quarter, after accounting for tax effects[12]. - The significant increase in net cash flow was primarily due to revenue growth and receipt of government subsidies[15]. Research and Development - Research and development expenses were CNY 5,661,139.07, remaining stable compared to CNY 5,619,822.65 in the previous period[28]. - The company has successfully registered four new medical devices, including "hard meninges medical glue" and "titanium screws for craniofacial fixation," all classified as Class III medical devices[22]. Future Plans - The company plans to expand its market presence and invest in new technologies to drive future growth[29]. - The company has not disclosed any new strategies related to market expansion or mergers and acquisitions in the current report[21].
迈普医学(301033) - 2023 Q1 - 季度财报